Cancer News

PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer (10/09/2019)

Maintenance therapy with the PARP inhibitor Lynparza (olaparib) added to Avastin (bevacizumab) resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer  according to the results of the phase 3 PAOLA-1/ENGOT-ov25 study presented at the European Society for Medical Oncology (ESMO) Congress 2019. (1) About Lynparza... Continue Reading

Lynparza-Avastin Maintenance Delays Progression of Ovarian Cancer (08/20/2019)

Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza (olaparib) plus Avastin (bevacizumab) compared to Avastin alone in women with or without BRCA gene mutations have been released and the combination delays cancer progression. (1) About Ovarian Cancer Ovarian cancer is the eighth most common... Continue Reading

NCCN Updates Ovarian Cancer Guidelines (03/26/2019)

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes. All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2 testing performed. Maintenance Therapy: Lynparza (olaparib) was added as a maintenance therapy option after complete or partial clinical remission... Continue Reading

About The National Ovarian Cancer Coalition (08/29/2018)

Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site ( that includes active message boards, educational booklets, and a toll-free helpline, the organization is prepared to …

Continue reading "About The National Ovarian Cancer Coalition"

Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient (06/18/2018)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer often goes undiagnosed until it has reached the later stages, when it is harder to treat. Information and support and are key to …

Continue reading "Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient"

PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer (05/16/2018)

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in New Orleans, Louisiana.  Preliminary results from the study suggest that the combination could provide meaningful …

Continue reading "PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer"

Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer (04/09/2018)

CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. About Rubraca® Rubraca® is …

Continue reading "Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer"

It’s in the Genes: Genetic Testing for Ovarian Cancer  (03/15/2018)

What your DNA reveals and why it’s worth knowing CancerConnect News: Ovarian cancer is often dubbed as the “silent killer” of women. The symptoms are vague—including bloating, fatigue, irregular bleeding, frequent urination, and back pain1 —making it difficult to diagnose early. By way of comparison, detection and treatment of breast cancer has progressed tremendously. This …

Continue reading "It’s in the Genes: Genetic Testing for Ovarian Cancer "

Chemo Bath Improves Ovarian Cancer Survival (01/22/2018)

CancerConnect News: A heated chemotherapy bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer, according to the results of a study published in the prestigious New England Journal of Medicine this week.1 About Ovarian Cancer Each year in the United States, roughly 22,000 women are diagnosed with …

Continue reading "Chemo Bath Improves Ovarian Cancer Survival"

Rubraca Significantly Improves Survival Ovarian Cancer (01/18/2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken poly ADP-ribose polymerase (PARP) inhibitor that works by blocking PARP1, PARP2 and PARP3 enzyme involved in repairing damaged DNA. By …

Continue reading "Rubraca Significantly Improves Survival Ovarian Cancer"